A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University
About this trial
This is a clinical study of personalized self-DC vaccine targeting neo-antigen (Neo-DC vaccine) in the treatment of advanced solid tumors.
Eligibility criteria
Qualifiers
18-75 years.
Histologically or cytologically confirmed advanced solid tumor, with at least one tumor lesion measurable (basis RECIST1.1 standard).
HLA typing was HLA-A0201/1101/2402 (containing at least one of the typing, according to the central laboratory issued).
Paraffin-embedded tumor tissue sections or biopsy tumor tissues within 3 years (for tumors with easy sampling).
Disqualifiers
Pregnant or lactating women.
Patients with a history of severe immediate allergies to the cells and any drugs used in this study.
Those with a history of organ transplantation.
Known central nervous system metastasis.
Trial design
Treatments tested in this trial
- DC Vaccine
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov